Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bladder-preservation study of enfortumab vedotin + pembrolizumab in muscle-invasive bladder cancer
CTR20262863Phase 2Active
- Sponsor
- 不适用/ 安斯泰来（中国）投资有限公司
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in muscle-invasive bladder cancer (MIBC), sponsored by 不适用/ 安斯泰来（中国）投资有限公司. Started Apr 2026; status: active.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on CTR20262863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262863.